PTC
CORT icon

Private Trust Company’s Corcept Therapeutics CORT Stock Holding History

Private Trust Company’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-150
Closed -$5.22K – 2624
2025
Q4 		$5.22K Hold
150
– – ﹤0.01% 2155
2025
Q3 		$12.5K Hold
150
– – ﹤0.01% 1821
2025
Q2 		$11K Sell
150
-40
-21% -$2.9K ﹤0.01% 1783
2025
Q1 		$21.7K Sell
190
-32
-14% -$1.95K ﹤0.01% 1517
2024
Q4 		$11.2K Hold
222
– – ﹤0.01% 1719
2024
Q3 		$10.3K Hold
222
– – ﹤0.01% 1718
2024
Q2 		$7.21K Sell
222
-24
-10% -$657 ﹤0.01% 1802
2024
Q1 		$6.2K Buy
+246
New +$5.81K ﹤0.01% 1830

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Private Trust Company's CORT Position: Q1 2026 in Review

Private Trust Company sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 150 shares — an estimated $5.22K sold.

Private Trust Company first reported a position in CORT in Q1 2024 and held it in 8 quarters. The position peaked at $21.7K in Q1 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Private Trust Company reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Private Trust Company sold 150 Corcept Therapeutics shares in Q1 2026, an estimated $5.22K.
  • Private Trust Company first reported a position in Corcept Therapeutics in Q1 2024 and held it in 8 quarters.
  • Private Trust Company's Corcept Therapeutics position peaked at $21.7K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Private Trust Company's 13F filing for Q1 2026, filed 30 Apr 2026.